4.1 Review

Investigational Antiplatelet Drugs for the Treatment and Prevention of Coronary Artery Disease

期刊

CARDIOLOGY IN REVIEW
卷 16, 期 5, 页码 250-259

出版社

LIPPINCOTT WILLIAMS & WILKINS
DOI: 10.1097/CRD.0b013e3181804336

关键词

antiplatelet drugs; adenosine diphosphatase receptor antagonists; thromboxane inhibitors; protease-activated receptor antagonists; thrombin inhibitors; anti-von Willebrand agents

向作者/读者索取更多资源

Antiplatelet therapy for the prevention and treatment of coronary artery disease (CAD) has undergone dramatic changes and improvements. Aspirin remains the first-line antiplatelet drug for clinical use. Newer platelet inhibitors such as the thienopyridine agents, ticlopidine and clopidogrel, have also been shown to be effective in treating CAD. There have been ongoing efforts to evaluate newer antiplatelet drugs, with the potential to improve clinical efficacy and safety. Some of the more promising antiplatelet agents include new adenosine diphosphate receptor antagonists such as prasugrel, cangrelor, and ticagrelor (AZD6140). In addition, a new thromboxane receptor antagonist, NCX-4016, a newly discovered protease-activated receptor antagonist that targets thrombin-induced platelet aggregation, and anti-von Willebrand factor aptamers show tremendous promise in refining antiplatelet therapy by targeting different receptors and molecules.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.1
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据